Phase 2a Study of alxn1007, a Novel c5a Inhibitor, in Subjects with Newly Diagnosed Acute Graft-Versus-Host Disease (gvhd) Involving the Lower Gastrointestinal Tract

A. M. Alousi, University of Texas MD Anderson Cancer Center
B. Yao, Alexion Pharmaceuticals Inc.
B. Overman, University of Texas MD Anderson Cancer Center
V. Ratanatharathorn, Karmanos Cancer Center
S. Gill, University of Pennsylvania
G. Socie Hospital, Hôpital Saint-Louis
Y. Dai, Alexion Pharmaceuticals Inc.
S. Chasan-Taber, Dartmouth College

Abstract